Tevogen Bio Holdings Inc
For the period ended Dec 31, 2023. Filed Apr 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 29, 2024
TVGN$5.84+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
| For the | For the | |
|---|---|---|
| Year Ended | Year Ended | |
| December 31, | December 31, | |
| 2023 | 2022 | |
| General and administrative | $2,273,970 | $953,083 |
| Total operating expenses | (2,273,970) | (953,083) |
| Other income (expense): | ||
| Unrealized gain on investments held in Trust Account | 2,734,426 | 4,948,194 |
| Change in fair value of warrants | (21,750) | 413,250 |
| Impairment of amount due from related party | (250,000) | — |
| Interest expense | (256,031) | — |
| Total other income, net | 2,206,645 | 5,361,444 |
| Net (loss) income | $(67,325) | $4,408,361 |
| Weighted average shares outstanding of Class A Ordinary shares | 5,333,742 | 34,500,000 |
| Basic and diluted net income (loss) per share, Class A (redeemable) | $0.00 | $0.09 |
| Weighted average shares outstanding of Class A Ordinary shares | 12,317,077 | 1,450,000 |
| Basic and diluted net income (loss) per share, Class A (non-redeemable) | $0.00 | $0.09 |
| Weighted average shares outstanding of Class B Ordinary shares | 1,116,256 | 11,983,333 |
| Basic and diluted income (loss) per share, Class B | $0.00 | $0.09 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.